Results 91 to 100 of about 2,408 (165)

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. [PDF]

Medicina (Kaunas), 2023
Napolitano L, Manfredi C, Cirillo L, Fusco GM, Passaro F, Abate M, La Rocca R, Mastrangelo F, Spirito L, Pandolfo SD, Crocetto F, Arcaniolo D, Barone B.   +12 more
europepmc   +1 more source

Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes. [PDF]

World J Urol
Le QC, Longoni M, Marmiroli A, Falkenbach F, Catanzaro C, Nicolazzini M, Polverino F, Goyal JA, Saad F, Schiavina R, Carmignani LF, Briganti A, Longo N, Graefen M, Palumbo C, Traumann M, Chun FK, Karakiewicz PI.   +17 more
europepmc   +1 more source

Predictors of survival after cytoreductive nephrectomy in metastatic renal cell carcinoma: A Real-world perspective. [PDF]

Indian J Urol
Menon AR, Pooleri GK, Sukumaran SV, Nuthalapati M, Patil VD, Agrawal S, Nazareth S, Rajendran R, Mathew G, Mohan M, Nair K, Vasudevan SK, Thomas A.   +12 more
europepmc   +1 more source

Deferred Versus Upfront Cytoreductive Nephrectomy in MetaStatic Renal Cell Carcinoma: Comparative Survival Analysis in the Immunotherapy Era. [PDF]

Cancers (Basel)
Xu T, Tuerxun P, Liu N, Ji C, Zhao K, Qian Y, Abudushataer A, Li Y, Jiang X, Xiong Z, Wang M, Jia R, Ge YZ.   +12 more
europepmc   +1 more source

Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered

Current Opinion in Urology, 2020
Luis, Meza, Alexander, Chehrazi-Raffle, Sumanta Kumar, Pal   +2 more
openaire   +3 more sources

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]. [PDF]

Eur Urol Open Sci
Bickley L, Fransen van de Putte EE, van den Brink L, Marandino L, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Tippu Z, Turajlic S, Bex A.   +14 more
europepmc   +1 more source

Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy. [PDF]

J Urol
Ghasemzadeh A, Abel EJ, Karam JA, Spiess PE, Peyton CC, Manley BJ, Sirard RB, Robertson N, Ellis EE, Cotta BH, Patel KR, Nicaise E, Jani A, Sexton WJ, Patil D, Allen GO, Matin SF, Master VA, Shapiro DD.   +18 more
europepmc   +1 more source

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials. [PDF]

Eur Urol Open Sci
Bickley L, Fransen van de Putte EE, van den Brink L, Marandino L, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Tippu Z, Turajlic S, Bex A.   +14 more
europepmc   +1 more source

NLR as prognostic biomarker for metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy. [PDF]

Biomark Med
Liu H, Li S, Zhang F, He W, Gou X, Zhang X, Xie Y.   +6 more
europepmc   +1 more source

Utilization of Partial Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma. [PDF]

J Clin Med
Hauser N, Giakas J, Robinson H, Davaro F, Hamilton Z.   +4 more
europepmc   +1 more source